Macquarie Group’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.56M Sell
8,512
-17,897
-68% -$3.3M 0.01% 572
2025
Q4
$4.65M Sell
26,409
-27,352
-51% -$4.47M 0.02% 414
2025
Q3
$7.53M Sell
53,761
-1,563
-3% -$211K 0.01% 867
2025
Q2
$6.95M Sell
55,324
-3,780
-6% -$471K 0.01% 898
2025
Q1
$8.09M Buy
59,104
+6,144
+12% +$878K 0.01% 854
2024
Q4
$7.23M Buy
52,960
+7,297
+16% +$1.23M 0.01% 869
2024
Q3
$8.85M Sell
45,663
-10,166
-18% -$2.13M 0.01% 839
2024
Q2
$12.9M Sell
55,829
-64,892
-54% -$14.1M 0.01% 757
2024
Q1
$26M Sell
120,721
-134,394
-53% -$31.5M 0.03% 614
2023
Q4
$66M Sell
255,115
-17,992
-7% -$4.42M 0.08% 359
2023
Q3
$70.2M Buy
273,107
+207,708
+318% +$55.6M 0.09% 305
2023
Q2
$18.6M Buy
65,399
+6,059
+10% +$1.8M 0.02% 662
2023
Q1
$16.5M Buy
59,340
+6,358
+12% +$1.76M 0.02% 705
2022
Q4
$14.7M Buy
52,982
+874
+2% +$247K 0.02% 758
2022
Q3
$13.9M Buy
52,108
+329
+0.6% +$69.9K 0.02% 756
2022
Q2
$10.6M Sell
51,779
-3,384
-6% -$692K 0.01% 854
2022
Q1
$11.6K Sell
55,163
-1,453
-3% -$316K 0.01% 906
2021
Q4
$13.6M Sell
56,616
-15,769
-22% -$4.05M 0.01% 865
2021
Q3
$20.5M Buy
72,385
+1,610
+2% +$528K 0.02% 763
2021
Q2
$24.5M Buy
70,775
+944
+1% +$286K 0.02% 726
2021
Q1
$19.5M Buy
69,831
+44
+0.1% +$11.9K 0.03% 531
2020
Q4
$17.1M Sell
69,787
-706
-1% -$182K 0.03% 571
2020
Q3
$20M Buy
70,493
+3,025
+4% +$844K 0.03% 469
2020
Q2
$18.1M Sell
67,468
-66,904
-50% -$20.1M 0.03% 485
2020
Q1
$42.5M Buy
134,372
+3,213
+2% +$975K 0.09% 247
2019
Q4
$38.9M Sell
131,159
-265,824
-67% -$73.8M 0.06% 358
2019
Q3
$92.4M Sell
396,983
-27,376
-6% -$6.37M 0.15% 111
2019
Q2
$99.2M Sell
424,359
-66,357
-14% -$15.3M 0.17% 106
2019
Q1
$116M Sell
490,716
-187,375
-28% -$59M 0.2% 89
2018
Q4
$204M Sell
678,091
-126,620
-16% -$40.4M 0.39% 40
2018
Q3
$284M Buy
804,711
+69,498
+9% +$23.9M 0.46% 40
2018
Q2
$213M Buy
735,213
+39,251
+6% +$11M 0.37% 49
2018
Q1
$191M Sell
695,962
-32,032
-4% -$9.94M 0.35% 46
2017
Q4
$232M Buy
727,994
+29,762
+4% +$9.55M 0.41% 46
2017
Q3
$219M Buy
698,232
+81,495
+13% +$24.1M 0.39% 47
2017
Q2
$167M Sell
616,737
-41,371
-6% -$10.9M 0.31% 55
2017
Q1
$180M Sell
658,108
-84,461
-11% -$23.9M 0.33% 51
2016
Q4
$211M Sell
742,569
-49,551
-6% -$14.7M 0.4% 45
2016
Q3
$248M Sell
792,120
-1,022,586
-56% -$303M 0.48% 45
2016
Q2
$439M Buy
1,814,706
+816,948
+82% +$215M 0.43% 49
2016
Q1
$260M Buy
997,758
+122,830
+14% +$32.4M 0.52% 48
2015
Q4
$268M Buy
874,928
+107,311
+14% +$30.8M 0.55% 47
2015
Q3
$224M Buy
767,617
+102,047
+15% +$33.7M 0.48% 53
2015
Q2
$269M Buy
665,570
+242,333
+57% +$97.3M 0.53% 49
2015
Q1
$179M Buy
423,237
+341,417
+417% +$135M 0.35% 64
2014
Q4
$27.8M Buy
81,820
+2,940
+4% +$951K 0.06% 316
2014
Q3
$26.1M Sell
78,880
-320
-0.4% -$106K 0.06% 319
2014
Q2
$25M Buy
79,200
+1,040
+1% +$313K 0.06% 311
2014
Q1
$23.9M Buy
78,160
+3,570
+5% +$1.13M 0.04% 311
2013
Q4
$20.9M Buy
74,590
+11,280
+18% +$2.92M 0.04% 325
2013
Q3
$15.2M Buy
63,310
+1,500
+2% +$336K 0.03% 372
2013
Q2
$13.3M Buy
+61,810
New +$13.2M 0.03% 380

Other funds holding BIIB

Macquarie Group's BIIB Position: Q1 2026 in Review

Macquarie Group reduced its Biogen (BIIB) stake by 68% in Q1 2026, selling an estimated $3.3M and leaving 8,512 shares worth $1.56M. The position accounts for 0.01% of the portfolio, ranked #572.

Macquarie Group first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $439M in Q2 2016. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Macquarie Group held 8,512 shares of Biogen worth $1.56M as of Q1 2026.
  • Macquarie Group sold 17,897 Biogen shares in Q1 2026, an estimated $3.3M.
  • Biogen made up 0.01% of Macquarie Group's portfolio in Q1 2026, its #572 holding.
  • Macquarie Group first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Macquarie Group's Biogen position peaked at $439M in Q2 2016.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Macquarie Group's 13F filing for Q1 2026, filed 15 May 2026.